Therapeutics MD | 8-K: FY2025 Q3 Revenue: USD 784 K

Revenue: As of FY2025 Q3, the actual value is USD 784 K.

EPS: As of FY2025 Q3, the actual value is USD 0.

EBIT: As of FY2025 Q3, the actual value is USD -862 K.

Net Income (Loss) from Continuing Operations

• Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.

License Revenues from Continuing Operations

• License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third quarter of 2025, an increase of $237 thousand compared to $547 thousand in license revenue for the third quarter of 2024. The increase is attributable to changes in sales of licensed products.

Total Operating Expenses from Continuing Operations

• Total operating expenses for the third quarter of 2025 were $1,646 thousand, a decrease of $35 thousand, or 2.1%, compared to the third quarter of 2024, reflecting minimal change from the third quarter of 2024.

Balance Sheet

• As of September 30, 2025, the Company’s cash and cash equivalents totaled $7.1 million.

Outlook / Guidance

• The Company continues to evaluate a variety of strategic alternatives that may include an acquisition, merger, other business combination, sale of assets, or other strategic transactions. There is no assurance of a transaction or successful outcome, and the Company has not set a timetable for completion of this exploration process.